The upgrade allows improves the performance of the printheads and is available in reel-to-reel or inline formats. The product targets the pharmaceutical sector and the system offers full digital four-colour print.
“Variations in product, dosage strength, pack sizes and local market requirements traditionally create the need for hundreds of different packaging variants,” said Roy Taylor, managing director of Hapa UK and Ireland. “With in-house late stage customisation, however, the need for huge inventory is largely alleviated: instead, companies can use blank or part-printed stock which, for the handling of complex production schedules with many short batches, delivers a host of benefits.
“Plus, with pharmaceutical manufacturers facing the most extreme demands on their product operations in years, late stage customization enables producers to satisfy customer demand almost immediately, thereby meeting the twin objectives of increasing customer satisfaction through reduced lead times, while improving operational efficiency and profitability – despite the challenges of Falsified Medicines Directive compliance.”
